Assembly Biosciences (NASDAQ:ASMB) Releases Quarterly Earnings Results

Assembly Biosciences (NASDAQ:ASMB) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, beating the consensus estimate of ($1.75) by $0.18, Zacks reports. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The firm had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.05 million.

Assembly Biosciences Trading Up 3.0 %

ASMB opened at $11.01 on Friday. The stock has a 50-day moving average price of $12.91 and a 200-day moving average price of $15.15. Assembly Biosciences has a 12-month low of $10.27 and a 12-month high of $19.93. The stock has a market capitalization of $69.98 million, a P/E ratio of -1.64 and a beta of 0.62.

Insider Transactions at Assembly Biosciences

In related news, Director Michael Houghton purchased 3,202 shares of Assembly Biosciences stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the transaction, the director now directly owns 3,202 shares in the company, valued at $49,983.22. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.